A randomised, phase II study of intetumumab, an anti-αv-integrin mAb, alone and with dacarbazine in stage IV melanoma

[1]  G. Nahler.  ECOG Performance Status , 2020, Definitions.

[2]  A. Pavlick,et al.  A phase II multicenter study of ipilimumab with or without dacarbazine in chemotherapy-naïve patients with advanced melanoma , 2011, Investigational New Drugs.

[3]  D. Schadendorf,et al.  Improved survival with ipilimumab in patients with metastatic melanoma. , 2010, The New England journal of medicine.

[4]  P. Schellhammer,et al.  Integrated data from 2 randomized, double‐blind, placebo‐controlled, phase 3 trials of active cellular immunotherapy with sipuleucel‐T in advanced prostate cancer , 2009, Cancer.

[5]  G. Linette,et al.  Double-blind randomized phase II study of the combination of sorafenib and dacarbazine in patients with advanced melanoma: a report from the 11715 Study Group. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  Donna Niedzwiecki,et al.  Meta-analysis of phase II cooperative group trials in metastatic stage IV melanoma to determine progression-free and overall survival benchmarks for future phase II trials. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  T. Byzova,et al.  Angiogenesis in melanoma. , 2007, Seminars in oncology.

[8]  Robert A. Beckman,et al.  Phase I Evaluation of a Fully Human Anti–αv Integrin Monoclonal Antibody (CNTO 95) in Patients with Advanced Solid Tumors , 2007, Clinical Cancer Research.

[9]  P. Kiener,et al.  Direct targeting of αvβ3 integrin on tumor cells with a monoclonal antibody, Abegrin™ , 2006, Molecular Cancer Therapeutics.

[10]  H. Pehamberger,et al.  Bcl-2 antisense (oblimersen sodium) plus dacarbazine in patients with advanced melanoma: the Oblimersen Melanoma Study Group. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  A. Pavlick,et al.  CNTO 95, a fully human monoclonal antibody to alpha-v integrins: results of a phase I/II study in patients with metastatic melanoma , 2006 .

[12]  J. Kirkwood,et al.  Re-evaluating the role of dacarbazine in metastatic melanoma: what have we learned in 30 years? , 2004, European journal of cancer.

[13]  M. Trikha,et al.  CNTO 95, a fully human monoclonal antibody that inhibits αv integrins, has antitumor and antiangiogenic activity in vivo , 2004, International journal of cancer.

[14]  M. Lens,et al.  Global perspectives of contemporary epidemiological trends of cutaneous malignant melanoma , 2004, The British journal of dermatology.

[15]  G. Tucker.  Alpha v integrin inhibitors and cancer therapy. , 2003, Current opinion in investigational drugs.

[16]  D. Mann.  Modelling Survival Data in Medical Research , 2003 .

[17]  M. Atkins.  Interleukin-2: clinical applications. , 2002, Seminars in oncology.

[18]  Martin F. Mihm,et al.  Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[19]  E. Jonasch,et al.  Interferon in oncological practice: review of interferon biology, clinical applications, and toxicities. , 2001, The oncologist.

[20]  M. Christian,et al.  [New guidelines to evaluate the response to treatment in solid tumors]. , 2000, Bulletin du cancer.

[21]  C. Begg,et al.  Phase III multicenter randomized trial of the Dartmouth regimen versus dacarbazine in patients with metastatic melanoma. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[22]  F. Mitjans,et al.  Integrin αVβ3 Promotes M21 Melanoma Growth in Human Skin by Regulating Tumor Cell Survival , 1999 .

[23]  D. Elder,et al.  Progression-related expression of beta3 integrin in melanomas and nevi. , 1999, Human pathology.

[24]  D. Bajorin,et al.  Prognostic factors in patients with metastatic malignant melanoma: A multivariate analysis , 1993, Cancer.

[25]  D. Cheresh,et al.  Involvement of integrin alpha V gene expression in human melanoma tumorigenicity. , 1992, The Journal of clinical investigation.

[26]  D. Elder,et al.  Integrin distribution in malignant melanoma: association of the beta 3 subunit with tumor progression. , 1990, Cancer research.

[27]  A. Srivastava,et al.  The prognostic significance of tumor vascularity in intermediate-thickness (0.76-4.0 mm thick) skin melanoma. A quantitative histologic study. , 1988, The American journal of pathology.

[28]  E. Krementz,et al.  Dimethyl triazeno imidazole carboxamide and combination therapy for melanoma IV. Late results after complete response to chemotherapy (central oncology group protocols 7130, 7131, and 7131A) , 1984, Cancer.

[29]  P. Kiener,et al.  Direct targeting of alphavbeta3 integrin on tumor cells with a monoclonal antibody, Abegrin. , 2006, Molecular cancer therapeutics.

[30]  A. Jemal,et al.  Cancer Statistics, 2004 , 2004, CA: a cancer journal for clinicians.

[31]  M. Hendrix,et al.  Molecular Role(s) for Integrins in Human Melanoma Invasion , 2004, Cancer and Metastasis Reviews.

[32]  M Van Glabbeke,et al.  New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. , 2000, Journal of the National Cancer Institute.

[33]  D. Schadendorf,et al.  Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[34]  F. Mitjans,et al.  Integrin alpha(v)beta3 promotes M21 melanoma growth in human skin by regulating tumor cell survival. , 1999, Cancer research.

[35]  P. Wingo,et al.  Cancer statistics, 1995 , 1995, CA: a cancer journal for clinicians.

[36]  N. Dubrawsky.  Cancer statistics , 1989, CA: a cancer journal for clinicians.

[37]  N. Cascinelli,et al.  Melanoma of the Skin , 1989 .

[38]  B K Armstrong,et al.  Melanoma of the skin. , 1984, British medical bulletin.

[39]  D.,et al.  Regression Models and Life-Tables , 2022 .